Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Constipation
Interventions: Survey, Rectal Expulsion Device use; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV Infections, Syphilis Infection
Interventions: Chembio HIV/Syphilis rapid Point of Care (POC) test, Laboratory-based HIV and syphilis testing; Diagnostic Test
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Transplantation, Respiratory Tract Infections, Pulmonary Infection
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anorexia Nervosa
Interventions: Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA); Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 15 Years to 30 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Fasting; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Outbreak Investigation
Interventions: Crowdsourced campaign package, Rapid Response Teams, Registry enrollment; Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 2,010 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Fasting
Interventions: r-metHuLeptin, placebo; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Zonisamide, Zonegran; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Parkinson Disease
Interventions: Fasting, No Intervention; Other
Lead sponsor: Northeastern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fibromyalgia
Interventions: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation; Device
Lead sponsor: Charles (Chuck) Raison; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy
Interventions: VBP15, Placebo; Drug
Lead sponsor: ReveraGen BioPharma, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Major Depressive Disorder
Interventions: Riluzole, Sertraline, placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Renal Cell
Interventions: Sorafenib (Nexavar, BAY43-9006), Interferon; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 9
States / cities: Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more

Conditions: Cocaine-Related Disorders
Interventions: Amantadine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chest Pain
Interventions: Somatom Force CT Scanner; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 85 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pharmacokinetics
Interventions: ESK-001, Rabeprazole; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cerebrovascular Accident
Interventions: TR intervention, In-home messaging device., Usual care; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 45 Years to 90 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Decatur, Georgia • Indianapolis, Indiana • Durham, North Carolina

Conditions: Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions: 2.0mg Buprenorphine/0.5mg Naloxone, Promethazine; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Hialeah, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Obstructive Sleep Apnea
Interventions: Upper airway collapsibility (Pcrit); Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 79 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Atrial Flutter, Tachycardia, Supraventricular, Tachycardia, Atrial Ectopic, Tachycardia, Reciprocating, Tachycardia Atrial, Tachycardia, Atrioventricular Nodal Reentry, Tachycardia, Paroxysmal, Fetal Hydrops
Interventions: Prospective observational cohorts; Other
Lead sponsor: Edgar Jaeggi; Other
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • San Francisco, California • Denver, Colorado + 15 more

Conditions: Echocardiography
Interventions: Education; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Hepatic Impairment, Healthy Participants
Interventions: Linzagolix; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: 14C-VX-407; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Propranolol Hydrochloride Extended Release Capsules 160 mg, INDERAL® LA 160 mg Capsules, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Search by objective public record fields.

A Rapid Clinical Care Pathway to Care for Patients Affected by Chronic Constipation

Implementation of an Opt-Out Testing and Rapid Diagnostic Strategy for Syphilis and HIV in Pregnant Patients Presenting to the Emergency Department

Rapid Detection of Airway Pathogens for Lung Transplantation

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

The Effect of Calorie Deprivation on Adipose Tissue Distribution

Leveraging Social Innovation and Community-Engagement to Reduce Disparities in Outbreak Control Outcomes

Role of Leptin in the Neuroendocrine and Immune Response to Fasting

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

Dance and Energy Expenditure Among Adults With Parkinson's

Whole Body Hyperthermia (WBH) as a Rapid Treatment for Fibromyalgia

A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

Riluzole Augmentation Pilot in Depression (RAPID) Trial

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4

Myocardial Stress Perfusion Computed Tomography in the Evaluation of Patients With Acute Chest Pain Using a Novel 3rd Generation Dual-source CT System

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

Home-based Telehealth Stroke Care: A Randomized Trial for Veterans

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Determination of Upper Airway Collapsibility During Routine CPAP Titration

Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia

Timing For Single View Bedside Cardiac Ultrasound

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose

A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fasting Conditions